Treats postoperative nausea and vomiting. ANDA 76546, held by Lupin. Trimethobenzamide Hydrochloride.
As of Nov 21, 2026, ANDA 76546 (Trimethobenzamide Hydrochloride), held by Lupin, was first approved by FDA on Aug 20, 2003, with 3 approved supplements and 0 published complete response letters.
Trimethobenzamide hydrochloride capsules is indicated in adults for the treatment of postoperative nausea and vomiting and for nausea associated with gastroenteritis. Limitation of Use: Trimethobenzamide hydrochloride capsules is not recommended for use in pediatric patients due to the risk of extrapyramidal signs and symptoms and other serious central nervous system (CNS) effects, and the risk of exacerbation of the underlying disease in pediatric patients with Reye's syndrome or other hepatic impairment.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 20, 2003 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Trimethobenzamide Hydrochloride300MG · capsule;oral | Trimethobenzamide Hydrochloride | Rx |
| Apr 22, 2020 | Supplement 10Labeling · Standard review | Approved | None posted |
| Jun 9, 2015 | Supplement 7Labeling | Approved | None posted |
| Feb 13, 2004 | Supplement 1Labeling | Approved | None posted |
| Aug 20, 2003 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters